AbbVie And Allergan: Five Big Review Questions To Worry About

Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.

Los Angeles, California, USA - June 30 2019 : Homepage of Abbvie .Official website of company . - Image

The proposed merger of AbbVie Inc. and Allergan PLC aims answer AbbVie’s biggest worry: competition for Humira (adalimumab), the world’s top-selling drug with sales of nearly $20bn last year.

Humira biosimilars are expected to launch in the US in 2023. The US Food and Drug Administration has already approved...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet